|
Valero-Lopez G, Millan-Pascual J, Iniesta-Martinez F, Delgado-Marin JL, Jimenez-Veiga J, Tejero-Martin AB, Leon-Hernandez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30). Mult Scler Relat Disord. 2022 Oct;66:104038. doi: 10.1016/j.msard.2022.104038. Epub 2022 Jul 7. PubMed PMID: 35870370.
AÑO: 2022; IF: 4.0
|
35870370
|
Fernandez-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascon-Gimenez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodriguez-Martin E, Roldan E, Villarrubia N, Saiz A, Blanco Y, Diaz-Perez C, Valero-Lopez G, Diaz-Diaz J, Aladro Y, Brieva L, Iniguez C, Gonzalez-Suarez I, Rodriguez de Antonio LA, Garcia-Dominguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Front Immunol. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. eCollection 2022. PubMed PMID: 35386690; PubMed Central PMCID: PMC8977599.
AÑO: 2022; IF: 7.3
|